Back to news

Halozyme Therapeutics gains as partner-drug approval, patent win, and bullish analyst call lift sentiment

Investivoq PriceTracker

Halozyme Therapeutics (HALO) is up 7.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a fresh royalty-growth catalyst after the FDA approved Roche’s Tecentriq Hybreza for stage III dMMR colon cancer, which expands use of a Halozyme-enabled product. Sentiment also seems to be benefiting from Halozyme’s recent patent injunction against Merck’s Keytruda SC in several European markets and a new price-target increase from TD Cowen.

Details:

  • On October 8, the FDA approved Tecentriq Hybreza for stage III dMMR colon cancer, broadening the commercial runway for a product that uses Halozyme’s drug-delivery technology.
  • Roche said the approval was supported by phase 3 ATOMIC data showing a 50% reduction in the risk of recurrence or death versus chemotherapy alone, which may strengthen expectations for future royalty streams tied to the product.
  • Halozyme said on October 7 that a Dutch court granted an injunction blocking manufacture and sale of Merck’s Keytruda SC across multiple European markets, removing some competitive and intellectual-property overhang.
  • TD Cowen also raised its price target on Halozyme to $130 from $105 while maintaining a Buy rating, adding momentum to an already favorable news cycle.

    • Sources:

    FDA, Roche, Halozyme Therapeutics, TipRanks

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $HALO Insider Trading Activity

    HALO Insider Trades

    $HALO insiders have traded $HALO stock on the open market 67 times in the past 6 months. Of those trades, 0 have been purchases and 67 have been sales.

    Here’s a breakdown of recent trading of $HALO stock by insiders over the last 6 months:

    • HELEN TORLEY (PRESIDENT AND CEO) has made 0 purchases and 53 sales selling 281,923 shares for an estimated $26,280,077.
    • MATTHEW L. POSARD has made 0 purchases and 8 sales selling 24,226 shares for an estimated $2,614,241.
    • MAHESH KRISHNAN sold 7,304 shares for an estimated $547,800
    • BERNADETTE CONNAUGHTON has made 0 purchases and 5 sales selling 6,501 shares for an estimated $502,549.

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    EARLY ACCESS
    Receive HALO Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $HALO Hedge Fund Activity

    We have seen 354 institutional investors add shares of $HALO stock to their portfolio, and 266 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • JUPITER ASSET MANAGEMENT LTD removed 1,510,447 shares (-93.9%) from their portfolio in Q2 2026, for an estimated $118,222,686
    • SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,322,613 shares (+inf%) to their portfolio in Q2 2026, for an estimated $103,520,919
    • CONGRESS ASSET MANAGEMENT CO added 1,052,509 shares (+85.6%) to their portfolio in Q3 2026, for an estimated $116,196,993
    • WASATCH ADVISORS LP added 1,049,647 shares (+inf%) to their portfolio in Q3 2026, for an estimated $115,881,028
    • MIZUHO MARKETS AMERICAS LLC removed 930,463 shares (-70.3%) from their portfolio in Q2 2026, for an estimated $72,827,339
    • CAPITAL WORLD INVESTORS removed 871,902 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $68,243,769
    • LOS ANGELES CAPITAL MANAGEMENT LLC added 842,119 shares (+76.8%) to their portfolio in Q2 2026, for an estimated $65,912,654

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $HALO Congressional Stock Trading

    Members of Congress have traded $HALO stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

    Here’s a breakdown of recent trading of $HALO stock by members of Congress over the last 6 months:

    • REPRESENTATIVE GILBERT RAY CISNEROS, JR. sold up to $15,000 on 09/29.

    To track congressional stock trading, check out Investivoq's congressional trading dashboard. You can access data on congressional stock trades through the Investivoq API Congress trades endpoint.

    $HALO Price Targets

    Multiple analysts have issued price targets for $HALO recently. We have seen 2 analysts offer price targets for $HALO in the last 6 months, with a median target of $94.0.

    Here are some recent targets:

    • Vikram Purohit from Morgan Stanley set a target price of $93.0 on 05/12/2026
    • Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $95.0 on 04/29/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.